Evidence map›Paper›PMID 38969874›Full record

ArticleAngiogenesis2024

A streamlined method to generate endothelial cells from human pluripotent stem cells via transient doxycycline-inducible ETV2 activation.

Allen Chilun Luo, Jiuhai Wang, Kai Wang, Yonglin Zhu, Liyan Gong, Umji Lee, Xiang Li, Daniel M Tremmel, Ruei-Zeng Lin, Donald E Ingber and 2 more

Abstract read
In one paragraph

Article in Angiogenesis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Allen Chilun LuoDepartment of Cardiac Surgery, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA.
Jiuhai WangWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02215, USA.
Kai WangDepartment of Cardiac Surgery, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA.
Yonglin ZhuDepartment of Cardiac Surgery, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA.
Liyan GongDepartment of Cardiac Surgery, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA.
Umji LeeDepartment of Cardiac Surgery, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA.
Xiang LiDepartment of Cardiac Surgery, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA.
Daniel M TremmelDepartment of Cardiac Surgery, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA.
Ruei-Zeng LinDepartment of Cardiac Surgery, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA.
Donald E IngberWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02215, USA.
James GormanWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02215, USA.
Juan M Melero-MartinDepartment of Cardiac Surgery, Boston Children's Hospital, 300 Longwood Ave, Boston, MA, 02115, USA. juan.meleromartin@childrens.harvard.edu.

Funding

Vascular networks genetically engineered for protein drug deliveryR01HL128452 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI MELERO-MARTIN, JUAN M, WANG, BO · 2015 to 2024
$4.8M
Enhancing endothelial cell engraftment via transplantation of exogenous mitochondriaR01HL152133 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI Juan M Melero-Martin · 2021 to 2026
$3.1M
Regulation of endothelial cell specificationR01HL151450 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI MELERO-MARTIN, JUAN M, PU, WILLIAM TSWENCHING · 2021 to 2024
$2.5M
Pericyte contribution to capillary remodeling in pulmonary arterial hypertensionR01HL171405 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI Juan M Melero-Martin, Ke Yuan · 2024 to 2026
$2.4M
Human endothelial cell regulation of ossificationR01AR080086 · NIAMS · BOSTON CHILDREN'S HOSPITAL · PI Juan M Melero-Martin · 2022 to 2026
$2.1M
NHLBI NIH HHS R01 HL128452NHLBI NIH HHS R01 HL151450NHLBI NIH HHS R01 HL152133NHLBI NIH HHS R01 HL171405NIAMS NIH HHS R01 AR080086
6 · The paper itself

Abstract

The development of reliable methods for producing functional endothelial cells (ECs) is crucial for progress in vascular biology and regenerative medicine. In this study, we present a streamlined and efficient methodology for the differentiation of human induced pluripotent stem cells (iPSCs) into induced ECs (iECs) that maintain the ability to undergo vasculogenesis in vitro and in vivo using a doxycycline-inducible system for the transient expression of the ETV2 transcription factor. This approach mitigates the limitations of direct transfection methods, such as mRNA-mediated differentiation, by simplifying the protocol and enhancing reproducibility across different stem cell lines. We detail the generation of iPSCs engineered for doxycycline-induced ETV2 expression and their subsequent differentiation into iECs, achieving over 90% efficiency within four days. Through both in vitro and in vivo assays, the functionality and phenotypic stability of the derived iECs were rigorously validated. Notably, these cells exhibit key endothelial markers and capabilities, including the formation of vascular networks in a microphysiological platform in vitro and in a subcutaneous mouse model. Furthermore, our results reveal a close transcriptional and proteomic alignment between the iECs generated via our method and primary ECs, confirming the biological relevance of the differentiated cells. The high efficiency and effectiveness of our induction methodology pave the way for broader application and accessibility of iPSC-derived ECs in scientific research, offering a valuable tool for investigating endothelial biology and for the development of EC-based therapies.

Indexed as

Cell DifferentiationDoxycyclineEndothelial CellsInduced Pluripotent Stem CellsTranscription FactorsAnimalsHumansMiceNeovascularization, PhysiologicDoxycyclineETV2 protein, humanTranscription FactorsAngiogenesisDoxycycline-inducibleEndothelial cell differentiationETV2Induced pluripotent stem cells (iPSCs)Vasculogenesis

Identifiers

PMID38969874
PMCPMC11577265

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.